

FOUNDATION CHILD WELL (STICHTING KIND BETER) AT DEN HAAG

Annual Report 2020



Stichting Kind Beter • P.O. box 82048 • 2508 EA Den Haag • The Netherlands +31(0)6-21513762 • kindbeter@ziggo.nl • KVK nummer/Chamber of Commerce: 71725261 RSIN/Tax number: 858824693 • kindbeter.nl



CONTENTS **AUDITOR'S REPORT** 1 Engagement Compilation report 2 **MANAGEMENT REPORT** 1 FINANCIAL STATEMENTS 1 Balance sheet as at December 31, 2020 2 Profit and loss account over 2020 3 4 Notes to the financial statements

- Notes to the balance sheet as of December 31, 2020
- 5 Notes to the profit and loss account 2020

Page

3

3

4

7

8

9

11

13



To the management of Foundation Kind Beter Brusselselaan 12 2587 AH Den Haag

Reference	Processed by	Date
19110	WKO	7th of April 2021

Dear management,

We hereby send you the report regarding the financial statements for the year 2020 of the foundation .

1 ENGAGEMENT

In accordance with your instructions we have compiled the annual account 2020 of the foundation, including the balance sheet with counts of \in 90,348 and the profit and loss account with a result of \in 54,632.

2 COMPILATION REPORT

Introduction

In accordance with your instructions we have compiled the financial statements 2020 of Stichting Kind Beter in Den Haag, which comprise the balance sheet as at December 31, 2020, the profit and loss account for 2020 and the notes.

Management's responsibility

The distinctive feature of a compilation engagement is that we compile financial information based on information provided by management of the entity. Management is responsible for the accuracy and completeness of the information provided and the financial statements based thereon.

Confirmation

Based on the information provided to us, we have compiled the financial statements using the accounting policies as included in Part 9 of Book 2 of the Dutch Civil Code.



1 MANAGEMENT REPORT

Background:

In 2012 our son Fenn was born. At first he seemed like an ordinary boy, but it soon turned out that he has a rare condition.

The genetic abnormality on the FoxP1 gene has only recently been discovered and no fundamental research has been carried out yet into the cause and a possible cure. Currently, there are about 100 children internationally known with this abnormality. The degree to which this syndrome manifests itself varies from child to child.

A research program has been defined together with the medical university of Leiden (LUMC). Stichting Kind Beter (Child Better Foundation) has been set up to organize the finance for this project.

When Stichting Kind Beter was set up in the beginning of 2018, the intention was that we would immediately get started with setting up a website, applying for ANBI status and raising funds. Unfortunately, for personal reasons, this did not work out immediately.

We only started setting up the website in Dutch and English at the end of 2018. By then we successfully applied for ANBI status.

Vision:

Everyone should be entitled to have access to medical treatment when needed. However, the market mechanism leaves ultra rare diseases to private initiatives. We believe that, with the right effort, people and organizations can be convinced to contribute to solutions for rare diseases.

Ambition:

A solution for FoxP1 within five years.

Covid 19 has delayed our process, but the ambition for developing a solution remains unaffected.

Objective:

In the first instance:

The funding of an investigation into the cause and a possible cure for the rare disease FoxP1 syndrome; Financing possible medical treatment / drugs to cure FoxP1 syndrome.

In the second instance:

Screening possible related diseases that may qualify for further analysis by this study .

General:

Developing and maintaining relevant relationships to promote the realization of the aforementioned objectives.

Organization and management:

The foundation did not employ any employees. The composition of the board has not changed in 2018. The board consists of volunteers.

We have expanded the team by two voluntary funding employees , Caroline Valk and Sylvia Bos. Also a parent couple with a FoxP1 child (Tom Wesseling and Annemiek Linn) actively started helping us.

In conclusion:

Our strategy is to apply for funding with institutional organizations which requires patience. Corona made it difficult to actively recruit. Not only are companies less inclined to donate, we also face more challenges on a personal level due to our son's homeschooling in the past lockdowns. Thanks to Tom and Annemiek's promotion, Walking in her shoes (walkinginhershoes.nl), we were able to collect a very nice amount in 2020. We hope to be able to get back to work in 2021 to raise funds and are hopeful for another nice amount in 2021.

We continue to fight for our ultimate goal: research into FoxP1 with other genetic diseases linked to it. Because every child deserves to get better.

- 4 -



Board of the Kind Beter Foundation; Chairman Andre de Koning Secretary Esther Kloosterman Treasurer Wilko Korving



- 5 -



FINANCIAL STATEMENTS






1 BALANCE SHEET AS AT DECEMBER 31, 2020


(before appropriation of results)

		December 31, 2020		December 31, 2019	
		€	€	€	€
ASSETS					
Fixed assets					
Financial fixed assets	(1)		15,000		-
Current assets					
Cash and cash equivalents	(2)		75,348		35,716






		December 31, 2020		December 31, 2019	
		€	€	€	€
EQUITY AND LIABILITIES					
Capital			90,348		35,497
Current liabilities	(3)				
Accruals and deferred income			-		219





2 PROFIT AND LOSS ACCOUNT OVER 2020

		2020		2019	
		€	€	€	€
Donations Cost of research	(4) (5)	39,749 -15,000		49,715 15,000	
Gross margin			54,749		34,715
Expenses					
Other operating expenses	(6)		117		332
Result Taxation on result from general operations		-	54,632	_	34,383
Result		=	54,632		34,383



- 8 -



3 NOTES TO THE FINANCIAL STATEMENTS

Activities

The foundation of Stichting Kind Beter was established by notarial deed on 23 May 2018. The objectives of the Foundation are:

Expanding knowledge with regard to FOXP1 in particular and other related genetic abnormalities. To fund related research and development of gene targeted therapies for FOXP1 and talented syndromes.

GENERAL PRINCIPLES FOR THE PREPARATION OF THE ANNUAL ACCOUNTS

The annual accounts have been prepared in accordance with Title 9 Book 2 of the Dutch Civil Code.

The annual accounts have been prepared based on the historical cost. Valuation of assets and liabilities and determination of the result takes place under the historical cost convention.

ACCOUNTING PRINCIPLES APPLIED TO THE VALUATION OF ASSETS AND LIABILITIES

Financial fixed assets

Loans to associates

Receivables from and loans to participating interests as well as other receivables are initially recognized at fair value and subsequently valued at amortized cost, which is equal to the nominal value, less any provisions deemed necessary.

Other receivables

The other receivables included under financial fixed assets include loans and other receivables, as well as purchased loans that will be held to maturity. These receivables are initially valued at fair value. Subsequently, these loans are valued at amortized cost. If there is a discount or premium on the granting of loans, this is credited or charged to the result as part of the effective interest during the term. Transaction costs are also included in the initial valuation and charged to the result as part of the effective interest. Impairments are deducted from the profit and loss account.

Cash and cash equivalents

The cash is valued at face value. If cash equivalents are not freely disposable, then this has been taken into account in the valuation.

Current liabilities

On initial recognition current liabilities are recognised at fair value. After initial recognition current liabilities are recognised at the amortised cost price, being the amount received taking into account premiums or discounts and minus transaction costs. This is usually the nominal value.

- 9 -




PRINCIPLES FOR THE DETERMINATION OF THE RESULT

General


The result is defined as the difference between the revenue from goods delivered and services performed on one hand and, on the other hand, the costs and expenses for that year, valued at historical costs.

Expenses general

Costs are determined on a historical basis and are attributed to the reporting year to which they relate.









2. Cash and cash equivalents

ING Bank N.V.

The cash equivalents are at free disposal.






EQUITY AND LIABILITIES

3. Current liabilities

Other liabilities and Accruals and deferred income

	12/31/2020	12/31/2019	
	€	€	
Accruals and deferred income			
Other accruals and deferred income		219	





5 NOTES TO THE PROFIT AND LOSS ACCOUNT 2020

	2020	2019
	€	€
4. Donations		
Donations	39,749	49,715
5. Cost of research		
Contribution to clinical genetics st. LUMC	-15,000	15,000
6. Other operating expenses		
Office expenses	-	205
Sales and distribution expenses General expenses	- 117	28 99
	117	332
Office expenses		
Printed matter	-	132
Automation costs		73
	-	205
Sales and distribution expenses		
Publicity and advertisement	-	28
General expenses		
Bank charges	117	99

- 13 -